Enliven Therapeutics Inc

NEW
NAS:ELVN (USA)  
$ 21.07 +0.16 (+0.76%) 12:08 AM EST
At Loss
P/B:
3.33
Enterprise V:
$ 740.77M
Volume:
406.08K
Avg Vol (2M):
220.53K
Trade In:
What is a stock summary page? Click here for an overview.
Volume:
406.08K
At Loss
Avg Vol (2M):
220.53K

Business Description

Enliven Therapeutics Inc
NAICS : 541714 SIC : 2834
ISIN : US29337E1029
Description
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
Name Current Vs Industry Vs History
Cash-To-Debt 3687.53
Equity-to-Asset 0.95
Interest Coverage No Debt
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 58.04
9-Day RSI 53.09
14-Day RSI 50.49
3-1 Month Momentum % -2.98
6-1 Month Momentum % -5.99
12-1 Month Momentum % 20.71

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 19.99
Quick Ratio 19.99
Cash Ratio 19.69

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -6
Shareholder Yield % -3.76

Financials (Next Earnings Date:2025-05-14 Est.)

ELVN's 30-Y Financials
Income Statement Breakdown FY
Not Enough Data
Balance Sheet Breakdown
Not Enough Data
Cashflow Statement Breakdown
Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
Not Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:ELVN

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016

Enliven Therapeutics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $)
EPS (TTM) ($) -1.89
Beta -
3-Year Sharpe Ratio -
3-Year Sortino Ratio -
Volatility % 46.22
14-Day RSI 50.49
14-Day ATR ($) 1.121581
20-Day SMA ($) 20.66
12-1 Month Momentum % 20.71
52-Week Range ($) 15.96 - 30.03
Shares Outstanding (Mil) 49

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Enliven Therapeutics Inc Filings

Filing Date Document Date Form
No Filing Data

Enliven Therapeutics Inc Stock Events

Financials Calendars
Event Date Price ($)
No Event Data

Enliven Therapeutics Inc Frequently Asked Questions

What is Enliven Therapeutics Inc(ELVN)'s stock price today?
The current price of ELVN is $21.07. The 52 week high of ELVN is $30.03 and 52 week low is $15.96.
When is next earnings date of Enliven Therapeutics Inc(ELVN)?
The next earnings date of Enliven Therapeutics Inc(ELVN) is 2025-05-14 Est..
Does Enliven Therapeutics Inc(ELVN) pay dividends? If so, how much?
Enliven Therapeutics Inc(ELVN) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1